arrow
A

Alvaro Moreno-Aspitia

Mayo Clinic
H指数:34
被引数:4,840

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
2024-11-010
PRE
Safety and tolerability of multi-epitope HER2 peptide vaccines in combination with trastuzumab emtansine in HER2-positive breast cancer patients with residual disease after neoadjuvant chemotherapy
2024-03-220
PRE
Lasofoxifene versus fulvestrant for ERD/HER2L metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Lasofoxifene与fulvestrant治疗ESR1突变的ERD/HER2L转移性乳腺癌: 来自随机,II期ELAINE 1试验的结果

2023-12-0112
OA
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
2023-11-081
OA
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
2023-06-011
OAAI
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC)-NCI 10013

卡铂和紫杉醇联合或不联合阿特珠单抗治疗三阴性乳腺癌 (TNBC) 的随机2期研究-NCI 10013

2022-12-3018
OA